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Abstract Purpose: Early-onset
sepsis (EOS) is one of the main cau-
ses for the admission of newborns to
the neonatal intensive care unit.
However, traditional infection mark-
ers are poor diagnostic markers of
EOS. Pancreatic stone protein (PSP)
is a promising sepsis marker in adults.
The aim of this study was to investi-
gate whether determining PSP
improves the diagnosis of EOS in
comparison with other infection
markers. Methods: This was a pro-
spective multicentre study involving
137 infants with a gestational age of
[34 weeks who were admitted with
suspected EOS. PSP, procalcitonin
(PCT), soluble human triggering
receptor expressed on myeloid cells-1
(sTREM-1), macrophage migration
inhibitory factor (MIF) and C-reac-
tive protein (CRP) were measured at
admission. Receiver-operating char-
acteristic (ROC) curve analysis was
performed. Results: The level of
PSP in infected infants was signifi-
cantly higher than that in uninfected
ones (median 11.3 vs. 7.5 ng/ml,
respectively; p = 0.001). The ROC
area under the curve was 0.69 [95 %
confidence interval (CI) 0.59–0.80;
p \ 0.001] for PSP, 0.77 (95 % CI
0.66–0.87; p \ 0.001) for PCT, 0.66
(95 % CI 0.55–0.77; p = 0.006) for
CRP, 0.62 (0.51–0.73; p = 0.055) for
sTREM-1 and 0.54 (0.41–0.67;
p = 0.54) for MIF. PSP indepen-
dently of PCT predicted EOS
(p \ 0.001), and the use of both
markers concomitantly significantly
increased the ability to diagnose EOS.
A bioscore combining PSP ([9 ng/
ml) and PCT ([2 ng/ml) was the best
predictor of EOS (0.83; 95 % CI
0.74–0.93; p \ 0.001) and resulted in
a negative predictive value of 100 %
and a positive predictive value of
71 %. Conclusions: In this pro-
spective study, the diagnostic
performance of PSP and PCT was
superior to that of traditional markers
and a combination bioscore improved
the diagnosis of sepsis. Our findings
suggest that PSP is a valuable bio-
marker in combination with PCT in
EOS.
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Introduction
While the implementation of intrapartum antibiotic
prophylaxis has led to a significant decline of group B
streptococcal (GBS) neonatal sepsis [1, 2], morbidity
and mortality due to early-onset sepsis (EOS, presenting
within 72 h of age) remain high. The incidence of EOS
in term infants in developed countries is currently 0.5
per 1,000 live births, with a case fatality rate of 2 %. In
preterm babies, the incidence is as high as 5 per 1,000
live births with a mortality reaching 25 % [2–5]. EOS is
one of the main reasons for admitting term babies to the
neonatal intensive care unit (NICU) and therefore
imposes a considerable economic burden on the health-
care system [6]. It is crucial to promptly identify infants
with EOS, since delaying antibiotic treatment is associ-
ated with neurologic impairment and increased mortality
[7, 8]. Due to the lack of specific clinical signs, infection
markers are commonly used to guide clinical decisions
to initiate or stop empiric antibiotic treatment [6].
However, the positive and negative predictive values
(PPV, NPV, respectively) of commonly used infection
markers, such as C-reactive protein (CRP), white blood
cell count (WBC) and immature by total ratio (I/T ratio)
to diagnose EOS are poor [9]. Combination biomarker
scores have been proposed to overcome the limitations
inherent to many sepsis markers [10]. Some of the most
promising marker candidates are procalcitonin (PCT),
soluble triggering receptor expressed on myeloid cells-1
(sTREM-1), macrophage migration inhibitory factor
(MIF) and pancreatic stone protein (PSP). PCT, a cal-
citonin precursor peptide of unknown physiological
function, has become an established sepsis marker in
adults and children [11]. PCT is known to show a
physiological increase during the first days of life [9].
sTREM-1 is the soluble form of a receptor expressed on
most phagocytic cells, and it becomes highly upregu-
lated during sepsis [12, 13]. MIF is a pro-inflammatory
mediator that is elevated in septic patients [14–16]. PSP
has recently emerged as a promising sepsis marker in
adults, with high PSP levels predicting sepsis, sepsis-
associated multiple-organ failure and mortality [17, 18].
However, no data are available on PSP in the clinical
setting of neonatal sepsis.
The aim of our study was to investigate the perfor-
mance of novel sepsis markers in neonates with EOS and
to determine whether a combination bioscore improves
the diagnosis of EOS.
Methods
Study subjects
This study is a subset study based on the prospective,
randomized-controlled multicentre Neonatal Procalcito-
nin Intervention Study (NeoPInS; see http://www.
clinicaltrials.gov; Trial no. NCT00854932) [19]. Patients
were recruited between 1 July 2009 and 31 December
2010 in three Swiss NICUs (University Children’s Hos-
pital Bern; Children’s Hospital Lucerne; Department of
Pediatrics, Cantonal Hospital Winterthur, Switzerland).
Neonates born after 34 0/7 weeks who were admitted
within the first 72 h of life to the NICU with suspicion of
sepsis and empirically treated for EOS were eligible for
enrolment in the study. At admission, blood was sampled
and routine laboratory tests were performed for evaluation
of neonatal infection (including CRP, PCT, I/T ratio and
WBC count). Children with congenital malformations
were excluded. The Ethics Committees of the Canton of
Berne, Canton of Zurich and Canton of Lucerne, Swit-
zerland, approved the study. Written consent from all
parents of participating infants was obtained at enrolment.
Diagnosis of infection
The likelihood of infection was assessed at 24–72 h after
admission into four categories based on culture results,
perinatal sepsis risk factors, clinical signs of sepsis and
laboratory test results [19]: (1) proven infection (positive
blood or cerebrospinal fluid cultures), (2) probable
infection (negative cultures, C3 abnormal findings), (3)
possible infection (negative cultures, two abnormal find-
ings) and (4) unlikely infection (negative cultures, single
abnormal finding). The following factors were consid-
ered: (1) maternal risk factors (GBS positivity, prolonged
rupture of membranes [18 h, chorioamnionitis), (2)
clinical symptoms (respiratory distress/apnea, tachycar-
dia/bradycardia, arterial hypotension/poor perfusion,
seizures/irritability, lethargy/feeding intolerance, ileus),
(3) results of conventional laboratory tests (WBC \5 9
109/l, CRP [10 mg/l, I/T ratio [0.2) and (4) results of
blood and cerebrospinal fluid cultures.
For this marker study, we a priori defined an infected
group (proven or probable infection) versus an uninfected
group (possible or unlikely infection). This is in agree-
ment with the study protocol that requires infants with
755
proven or probable infection to be treated for at least
7 days, whereas treatment is usually stopped after
24–72 h in infants with possible or unlikely infection.
Blood sampling
A sample of venous blood (100 ll) was obtained upon
admission of the infant to the NICU; this occurred
simultaneously with sampling for blood cultures, CRP,
WBC count and I/T ratio. Venous blood was taken by
venipuncture from a peripheral vein or from the umbilical
vein if an umbilical venous catheter was present. Samples
were centrifuged directly after sampling for 6 min at
3,000 g, and the serum obtained was immediately frozen
in sterile tubes at -80 C. All measurements were per-
formed when the study was finished.
In order to describe changes in PSP over the first days
of life, we also measured PSP in cord blood of 56 unin-
fected neonates born after 34 weeks gestational age and
postnatally in uninfected infants from this study, including
sequential samples during the first 5 days of life. Cord
blood was collected immediately after delivery of the child
from the umbilical vein at the placental side of the cord.
Infection marker measurements
Procalcitonin
Plasma PCT concentrations were measured using a time-
resolved amplified cryptate emission (TRACE) technol-
ogy assay (Kryptor PCT; BRAHMS, Hennigsdorf,
Germany).
C-reactive protein
C-reactive protein was determined using the Tina-Quant
C-Reactive Protein Gen 3 assay (Roche Diagnostics,
Indianapolis, IN) on a Roche Modular P800 system. CRP
levels below the detection limit were set at 1 mg/l for the
analyses.
Macrophage migration inhibiting factor
The levels of MIF were measured by an enzyme-linked
immunosorbent assay (ELISA) using the 4-span
approach, as described previously [20]. Briefly, microtiter
plates were coated with a duck anti-chicken antibody.
Anti-human MIF polyclonal antibodies raised in chicken
and rabbit were used as capture and trapping antibodies.
A horseradish peroxidase-labeled goat anti-rabbit anti-
body (Sigma, St. Louis, MO) was used for detection, and
recombinant human MIF was used as a standard. The
analytical sensitivity of the human MIF ELISA was
39 pg/ml. Intrarun and interrun coefficients of variation
were 6 and 12 %, respectively.
Soluble triggering receptor expressed on myeloid cells-1
Human serum sTREM-1 levels were determined by an in-
house optimized ELISA using the anti-human TREM-1
monoclonal antibody clone 6B1.1G12 (generous gift from
M. Radsak, University of Mainz, Germany [21]) at 10 lg/
ml for coating and reagents from the Human TREM-1
Duoset (R&D Systems, Minneapolis, MN) for detection
(according to manufacturers’ instructions).
Pancreatic stone protein
The levels of PSP were determined using an isoform-
specific ELISA as previously described [18]. In brief,
serum collected from the patient was incubated with
guinea pig anti-human PSP/reg antibody precoated plates.
Rabbit anti-human PSP/reg was added and subsequently
detected by phosphatase-conjugated anti-rabbit immuno-
globulin G. The detection limit was \0.1 ng/ml and the
interplate variance was \10 %.
Statistical methods
Because of non-normal distributions, measurements are
reported as medians and ranges. Correlations were
assessed using Spearman’s rank test for univariate anal-
yses and linear regression for multivariate analysis.
Differences between the infected and uninfected groups
were assessed using the Mann–Whitney test. Receiver-
operating characteristic (ROC) curve analysis was used to
assess the performance of each test. Optimal cut-offs were
evaluated based on ROC curves using the Yuden’s index.
Sepsis markers with a significance of p \ 0.10 were
included in the biomarker score models. The bioscore was
based on a scoring system which attributed one point for
each biomarker with a value above the cut-off point.
Bioscores were constructed using two, three and four
sepsis markers. In addition, we performed multivariate
logistic regression analyses to investigate the strength of
association between sepsis markers or bioscore models
with EOS. Models were adjusted for gestational age, birth
weight, sex and postnatal age at study sampling. Sensi-
tivity analyses were performed comparing PSP levels in
infected infants with those in (1) healthy newborns (cord
blood) and (2) the subgroup of included infants with
unlikely infection; both confirmed the main results
(details not shown).
A p level\0.05 was considered to be significant. SPSS
ver. 18.0 software was used (SPSS, Chicago, IL).
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Results
Description of the study population
During the study period, 170 infants who met the inclu-
sion criteria were admitted with suspected EOS. Fifteen
patients could not be included due to lack of informed
consent (10 parents denied consent, 5 were not approa-
ched), resulting in 155 infants eligible for entry into this
marker study. In 18 infants, the amount of sampled blood
was insufficient to perform additional laboratory analyses,
leaving 137 infants in whom PSP was determined. No
infant died. One infant required vasopressor support for
septic shock. Three infants developed positive blood
cultures, all with GBS. In total, 33/137 infants were
classified as infected (including 3 with proven infection
and 30 classified as probable infection), in contrast to 104
uninfected infants who were used as the control group (52
classified as possible infection and 52 as unlikely infec-
tion). Baseline characteristics of the infected versus the
uninfected group are shown in Table 1. Of all infants
enrolled in the study, 77 % were evaluated for EOS
within 24 h after delivery and 96 % within 48 h after
delivery.
PSP and infection markers in infected
versus uninfected infants
In the 137 children included in the EOS study, the median
PSP concentration was 8.8 [range 2.0–99.4, interquartile
range (IQR) 5.2–13.3] ng/ml. PSP concentration was
weakly correlated with birth weight (Spearman’s Rho
0.16; p = 0.08), gestational age (Rho 0.18; p = 0.03),
male sex (Rho 0.16; p = 0.06) and postnatal age at study
sampling (Rho 0.17; p = 0.04). PSP at admission corre-
lated significantly with CRP at admission (Rho 0.35;
p \ 0.001), maximal CRP during hospitalization (Rho
0.46; p B 0.001), PCT (Rho 0.23; p = 0.028), sTREM-1
(Rho 0.21; p = 0.025) and WBC count (Rho -0.23;
p = 0.008), but not with MIF or I/T ratio. PSP was sig-
nificantly higher in infected infants than in uninfected
infants (median 11.3 vs. 7.5 ng/ml, respectively; Mann–
Whitney p = 0.001; Fig. 1). Infected infants had signifi-
cantly higher PCT than unifected infants (median 20.33
vs. 2.0 ng/ml, respectively; p \ 0.001), higher CRP (6 vs.
1 mg/l, respectively; p = 0.004) and trendwise higher
sTREM-1 levels (1,436 vs. 1,234 pg/ml, respectively;
p = 0.055), while MIF levels, I/T ratio and WBC were
not significantly different between the groups (p [ 0.1).
ROC curve analysis to diagnose EOS
Pancreatic stone protein and PCT performed best among
all parameters studied to distinguish infected infants from
uninfected infants (Table 2). The ROC area under the
curve (AUC) was 0.69 [95 % confidence interval (CI)
0.59–0.80; p \ 0.001] for PSP and 0.77 (95 % CI
0.66–0.87; p \ 0.001) for PCT. The AUC was 0.66
(p = 0.006) for CRP and 0.62 for sTREM-1 (p = 0.055),
whereas the AUC for the other markers studied were not
significant. Based on ROC analyses, the optimal cut-off
for each sepsis marker was defined and compared
(Table 2). A cut-off for PSP of [9 ng/ml resulted in a
sensitivity of 79 % and a specificity of 62 % with a NPV
of 90 %.
Performance of bioscores to predict EOS
Based on the ROC curve analyses, PSP, PCT, sTREM-1
and CRP were included in the bioscore models. Bioscores
Table 1 Baseline
characteristics of infected
versus uninfected patients
Characteristic Infected (n = 33) Uninfected (n = 104) p valuea
Male sex 18 (55 %) 68 (65 %) 0.26
Gestational age (weeks) 39.9 (34.0–41.6) 38.9 (34.0–42.0) 0.07
Birth weight (g) 3,335 (1,950–4,400) 3,060 (1,630–4,750) 0.52
Maternal GBS? status 8 (24 %) 18 (17 %) 0.38
Maternal fever subpartum 6 (18 %) 8 (8 %) 0.08
PROM 8 (24 %) 15 (14 %) 0.19
Intrapartum antibiotics 14 (42 %) 23 (22 %) 0.02
Fetal tachycardia 6 (18 %) 11 (11 %) 0.25
Cesarean section 23 (70 %) 54 (59 %) 0.30
Apgar 1 min 7 (1–9) 7 (2–9) 0.64
Apgar 5 min 8 (3–10) 8 (2–10) 0.77
Apgar 10 min 9 (3–10) 9 (2–10) 0.51
Umbilical artery pH 7.24 (6.89–7.42) 7.25 (6.80–7.42) 0.77
Age at study entry (h) 12 (2–67) 8 (0–72) 0.21
Data are presented as the median with the range in parenthesis, or as the number with the percentage
in parenthesis, where appropriate
GBS? Positive maternal group B streptococcus status, PROM prolonged rupture of membranes
a p value calculated with the Mann–Whitney test
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Fig. 1 Comparison of sepsis markers between infected and
uninfected infants. Dashed lines Cut-offs used in this study. The
medians with interquartile ranges (IQR) and p values (Mann–
Whitney test) are shown. PSP Pancreatic stone protein, PCT
procalcitonin, sTREM-1 soluble triggering receptor expressed on
myeloid cells-1, MIF macrophage migration inhibitory factor,
CRP C-reactive protein, WBC white blood cell count, I/T ratio
immature by total neutrophil ratio
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were constructed using two, three or four sepsis markers
(Table 2; Fig. 2). The bioscore based on PSP and PCT
performed best in terms of distinguishing infected infants
from uninfected infants, with an AUC of 0.83 (95 % CI
0.74–0.93; p \ 0.001) and was superior to PCT or PSP
alone. The combined PSP/PCT score had a NPV of 100 %
if both markers were below the cut-off and a PPV of 71 %
if both were positive.
Multivariate logistic regression models showed that
increased PSP and PCT were independent strong predic-
tors of EOS (Table 3), while other markers were not
significant. PSP showed the strongest association with
EOS with an odds ratio (OR) of 26.4 (p \ 0.001), fol-
lowed by PCT (OR 7.9, p = 0.038). The bioscore based
on PSP and PCT was significantly associated with EOS
with an OR of 20.0 (p \ 0.001) per increasing score.
Again, the bioscore based on PSP and PCT performed
similar to or better than the bioscores that included
sTREM-1 or CRP, suggesting that neither sTREM-1 nor
CRP provided additional independent information.
Changes in PSP concentrations over the first days
of life
Finally, we investigated the changes in PSP serum con-
centration during the first days of life in uninfected
infants. The median PSP concentration in cord blood was
6.2 ng/ml and increased slowly over the first days of life
(median values in ng/ml; day 1: 7.2; day 2: 7.7; day 3:
10.3; day 4/5: 13.7; see Fig. 3). PSP concentrations at
[48 h of life were significantly higher that that at\48 h
of life (p \ 0.01).
Discussion
In this prospective multicentre study on term and late
preterm infants with EOS, we show that the diagnostic
performance of PSP and PCT is superior to that of tra-
ditional sepsis markers and that a combination score may
improve the diagnosis of sepsis. Our preliminary findings
thus suggest that PSP is a valuable biomarker to diagnose
EOS, especially in combination with PCT. To the best of
our knowledge, this is the first study investigating PSP in
neonatal sepsis.
EOS remains one of the leading causes of NICU
admission in term and late preterm infants and causes an
estimated 390 deaths annually in the USA [22]. However,
overdiagnosis of EOS results in prolonged hospitalization,
unnecessary exposure to the toxicity of aminoglycosides
and a higher risk of necrotizing enterocolitis [23] and also
favours the development of bacterial resistance. The use
of sepsis markers may enable clinicians to safely reduce
the duration of hospitalization and antibiotic treatment
Table 2 Receiver-operating characteristic curve analysis and diagnostic performance for different infection markers and bioscores
Diagnostic parameters ROC AUC
(95 %-confidence
interval)
p value Cut-off Sensitivity
(%)
Specificity
(%)
PLR NLR PPV
(%)
NPV (%)
Individual biomarkers
PSP 0.69 (0.59–0.80) \0.001 [9.0 ng/ml 79 62 2.1 0.35 39 90
PCT 0.77 (0.66–0.87) \0.001 [2 ng/ml 88 51 1.8 0.24 39 92
sTREM-1 0.62 (0.51–0.73) 0.055 [1,250 pg/ml 75 52 1.6 0.48 34 87
MIF 0.54 (0.41–0.67) 0.54 [50 ng/ml 84 30 1.2 0.54 29 85
CRP 0.66 (0.55–0.77) 0.006 [20 mg/l 36 89 3.4 0.71 52 82
I/T ratio 0.56 (0.44–0.68) 0.28 [0.2 70 40 1.2 0.75 27 80
WBC 0.48 (0.35–0.60) 0.69 \5 or [15 9 109/l 58 51 1.2 0.83 27 79
Bioscore models
Two markers
PSP ? PCT 0.83 (0.74–0.93) \0.001 C1 (C1/2 positive) 100 28 1.4 0.0 33 100
2 (2/2 positive) 68 90 6.7 0.36 71 89
Three markers
PSP ? PCT ? sTREM-1 0.82 (0.72–0.92) \0.001 C1 (C1/3 positive) 100 22 1.3 0.0 32 100
C2 (C2/3 positive) 91 51 1.9 0.18 41 94
3 (3/3 positive) 55 93 8 0.49 75 85
Four markers
PSP ? PCT ? sTREM ? CRP 0.81 (0.71–0.91) \0.001 C1 (C1/4 positive) 100 22 1.3 0.0 32 100
C2 (C2/4 positive) 91 49 1.8 0.19 40 94
C3 (C3/4 positive) 59 86 4.4 0.47 62 85
4 (4/4 positive) 32 97 9.4 0.71 78 79
ROC AUC receiver-operating characteristic area under the curve,
PLR positive likelihood ratio, NLR negative likelihood ratio, PPV
positive predictive value, NPV negative predictive value, PSP
pancreatic stone protein, PCT procalcitonin, sTREM-1, soluble
triggering receptor expressed on myeloid cells-1, MIF macrophage
migration inhibiting factor CRP C-reactive protein, I/T ratio
Immature by total ratio, WBC white blood cells
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while improving early recognition of infants at high risk
[6, 9, 24]. Several studies have reported the significantly
superior performance of PCT in comparison to traditional
sepsis markers in the diagnosis of late-onset sepsis
[25–27]. However, the physiological increase of PCT
during the first 48 h of life limits the performance of PCT
in the setting of EOS [9]. This was demonstrated in a
recent meta-analysis by Vouloumanou et al. who found
that the AUC of PCT (0.95) was excellent to diagnose
neonatal late-onset sepsis, but was less efficient (AUC
0.78; 95 % CI 0.74–0.81) for EOS [28]. Based on this
rationale, we investigated whether a combination of novel
markers could improve the diagnosis of EOS.
In our study, increased PSP levels were strongly
associated with EOS independently of PCT and showed
the strongest risk prediction in multivariate models. While
the ROC curve analysis results were comparable between
PSP and PCT, a bioscore combining PSP and PCT sig-
nificantly improved the ability to diagnose EOS, with a
NPV of 100 % if neither PCT nor PSP were positive, and
a PPV of 71 % if both were positive. PSP has so far only
been studied in adults; in these studies it was shown to
accurately predict multi-organ failure and mortality in
patients with ventilator-associated pneumonia and post-
traumatic sepsis [17, 18]. Interestingly, maximum PSP
levels in our study cohort were lower than those in adults
with sepsis. We observed a slow increase in PSP con-
centrations over the first days of life. While this indicates
that optimal PSP cut-offs may need to be adjusted over
the first days of life, it is very unlikely that it relevantly
affected our finding of increased PSP levels in infected
infants: the age at blood sampling was not significantly
different between infected and uninfected infants, and
multivariate analyses were adjusted for age at blood
sampling. In addition, the sensitivity analyses limited to
neonates included \24 and \48 h of life confirmed the
main results (not shown). Based on these preliminary
results, we suggest that larger prospective trials are
required to assess whether the combination of PCT and
PSP can safely guide the decision to initiate or to stop
empirical antibiotic treatment in infants with suspected
EOS. We measured PSP in simultaneously obtained
capillary heel-prick versus venous samples and found a
good level of agreement (Rho 0.99, bias 3 %; details not
shown), suggesting that capillary sampling for PSP is
sufficiently accurate, which may facilitate further studies
in neonates.
Although sTREM-1 was trendwise associated with
EOS, sTREM-1 provided no additional independent
information in the bioscore models. Sarafidis et al.
recently reported elevated sTREM-1 levels in 52 new-
borns with suspected late-onset sepsis using a commercial
assay [12]. The performance of sTREM-1 in our study
was slightly weaker compared to their study. In contrast
to PCT, PSP and sTREM-1, no significant difference was
observed between MIF levels in infected versus non-
infected newborns. In both groups, MIF levels were
strikingly elevated compared to values reported in healthy
adults and adults with septic shock [29]. This finding is in
agreement with previous reports showing physiologically
elevated MIF levels in healthy term and premature new-
borns [30]. The absence of a difference in MIF levels
Fig. 2 Positive predictive values of different bioscores based on
two (a), three (b) and four (c) sepsis markers with the correspond-
ing 95 % confidence intervals (CI). Dashed line Regression line.
PSP pancreatic stone protein, PCT procalcitonin, sTREM-1 soluble
triggering receptor expressed on myeloid cells-1,CRP C-reactive
protein
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between the infected and the non-infected groups in our
study may be due to the fact that septic shock was a rare
event.
The strengths of this study include its protocol-based
prospective multicentre design, the use of clearly defined
clinical and laboratory criteria to diagnose EOS and the
inclusion of several novel infection markers. We used
combination biomarker score models to investigate whe-
ther combining infection markers increases diagnostic
accuracy [10]. Notably, the sensitivity, specificity and
AUC of PCT to diagnose EOS in our study obtained
results that were very similar to those of a recent meta-
analysis which reported pooled sensitivity for PCT of
76 % (95 % CI 68–82 %) with a specificity of 76 %
(95 % CI 60–87 %) [28].
A limitation of this study is the low incidence of
culture-proven EOS. The observed incidence of bactere-
mia is in agreement with data showing that culture-proven
EOS represents only a small fraction of the total burden of
EOS [5, 31]. A recent study reported that only 2.2 % of
infants evaluated for suspected bacterial infection had
proven bacteremia [32]. Exposure of neonates to maternal
antibiotic treatment during labor and delivery increases
the rate of false negative blood cultures. In addition, the
small blood volumes collected when obtaining blood
cultures (0.5–1.0 ml) and the high proportion of low
colony count bacteremia result in a diminished sensitivity
of blood cultures to diagnose sepsis [6, 33].
In conclusion, we report that combining PSP and PCT
improved the diagnosis of EOS in comparison to PCT
alone or to traditional sepsis markers. PSP represents a
promising novel biomarker for neonatal sepsis. Future
trials are needed to assess whether determining PSP and
PCT in infants with EOS can reduce unnecessary antibi-
otic treatment and shorten hospital stay [24].
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Table 3 Multivariate logistic regression models to predict early-onset sepsis
Individual marker models Marker p value Odds ratio (95 % CI)
Two individual markers PSP [9 ng/ml \0.001 22.8 (4.7–110.6)
PCT [2 ng/ml 0.001 16.6 (13.0–90.7)
Three individual markers PSP [9 ng/ml \0.001 28.2 (4.4–180.7)
PCT [2 ng/ml 0.02 9.0 (1.4–57.0)
sTREM-1 [1,250 pg/ml 0.33 2.3 (0.4–13.0)
Four individual markers PSP [9 ng/ml 0.001 26.4 (4.0–172.5)
PCT [2 ng/ml 0.038 7.9 (1.1–55.9)
sTREM-1 [1,250 pg/ml 0.33 2.4 (0.4–13.0)
CRP [20 mg/l 0.71 1.4 (0.2–9.5)
Bioscore models Scores p value Odds ratio (95 % CI)
Two markers (PSP, PCT) 0, 1, 2 \0.001 20.0 (5.2–77.2)
Three markers (PSP, PCT, sTREM-1) 0, 1, 2, 3 \0.001 7.4 (2.4–22.4)
Four markers (PSP, PCT, sTREM-1, CRP) 0, 1, 2, 3, 4 \0.001 4.4 (1.9–9.9)
Models are adjusted for gestational age, birth weight, sex and postnatal age at study sampling
PSP pancreatic stone protein, PCT procalcitonin, sTREM-1 soluble triggering receptor expressed on myeloid cells-1, CRP C-reactiveprotein
Fig. 3 Changes in PSP levels during the first days of life. Line in
boxes Median, boxes 25th and 75th percentiles, whiskers 5th and
95th percentile, dashed line cut-off of 9 ng/ml. p values of Mann–
Whitney U test are shown
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